These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10923219)

  • 1. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes.
    Mortensen HB; Lindholm A; Olsen BS; Hylleberg B
    Eur J Pediatr; 2000 Jul; 159(7):483-8. PubMed ID: 10923219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.
    Lindholm A; McEwen J; Riis AP
    Diabetes Care; 1999 May; 22(5):801-5. PubMed ID: 10332685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
    Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS
    Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.
    Home PD; Barriocanal L; Lindholm A
    Eur J Clin Pharmacol; 1999 May; 55(3):199-203. PubMed ID: 10379635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
    Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
    Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
    Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
    Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
    Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes.
    Danne T; Aman J; Schober E; Deiss D; Jacobsen JL; Friberg HH; Jensen LH;
    Diabetes Care; 2003 Aug; 26(8):2359-64. PubMed ID: 12882862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
    Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
    Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
    Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
    Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
    [No Abstract]   [Full Text] [Related]  

  • 15. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
    Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
    Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial.
    Ruan Y; Elleri D; Allen JM; Tauschmann M; Wilinska ME; Dunger DB; Hovorka R
    Diabetologia; 2015 Apr; 58(4):687-90. PubMed ID: 25537835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes.
    Frier BM; Ewing FM; Lindholm A; Hylleberg B; Kanc K
    Diabetes Metab Res Rev; 2000; 16(4):262-8. PubMed ID: 10934454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
    Lindström T; Hedman CA; Arnqvist HJ
    Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
    Hermansen K; Vaaler S; Madsbad S; Dalgaard M; Zander M; Begtrup K; Soendergaard K
    Metabolism; 2002 Jul; 51(7):896-900. PubMed ID: 12077738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.